These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6169139)

  • 1. Binding of urokinase to plasma proteinase inhibitors.
    Holmberg L; Lecander I; Astedt B
    Scand J Clin Lab Invest; 1980; 40(8):743-7. PubMed ID: 6169139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of plasmin and its complexes with alpha 2-antiplasmin and alpha 2-macroglobulin on secretion of proteinase and plasminogen inhibitors from peripheral mononuclear cells].
    Zhabin SG; Zorin NA; Musatov MI
    Vopr Med Khim; 1995; 41(3):34-7. PubMed ID: 8585176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of plasmin with alpha 2-macroglobulin and alpha 2-antiplasmin in the presence and absence of tranexamic acid.
    Takada A; Takada Y
    Thromb Res; 1980 Apr 1-15; 18(1-2):237-46. PubMed ID: 6157220
    [No Abstract]   [Full Text] [Related]  

  • 4. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmin inhibitors in different fibrinolytic treatment patterns.
    Lasierra J; Diez M; Perera C; Viladés E
    Haemostasis; 1981; 10(1):51-62. PubMed ID: 6162721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.
    Müllertz S; Thorsen S; Sottrup-Jensen L
    Biochem J; 1984 Oct; 223(1):169-77. PubMed ID: 6208893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of the modified form of human plasminogen by alpha 2-macroglobulin-plasmin complexes.
    Yamamoto J; Okamoto U; Morita S; Asada N; Yamaoka M
    Jpn J Physiol; 1985; 35(6):1013-21. PubMed ID: 2422420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional characterization of the inhibition of urokinase by alpha 2-macroglobulin.
    Straight DL; Hassett MA; McKee PA
    Biochemistry; 1985 Jul; 24(15):3902-7. PubMed ID: 2413880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. In vivo reaction of plasminogen activator with alpha 2-macroglobulin.
    Gonias SL; Einarsson M; Pizzo SV
    J Clin Invest; 1982 Aug; 70(2):412-23. PubMed ID: 6178757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.
    Harpel PC
    J Clin Invest; 1981 Jul; 68(1):46-55. PubMed ID: 6166634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower molecular weight species of alpha 2-macroglobulin-plasmin complexes in human plasma activated by urokinase.
    Yamamoto J; Okamoto U
    Nihon Ketsueki Gakkai Zasshi; 1985 Jul; 48(4):1090-9. PubMed ID: 2414954
    [No Abstract]   [Full Text] [Related]  

  • 12. Interaction of urokinase with alpha2-macroglobulin investigated by isoelectric focusing. Evidence for non-specific dissociable binding.
    Vahtera E; Hamberg U
    Biochem J; 1978 Jun; 171(3):767-70. PubMed ID: 78704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assay of urokinase activity in plasma with a chromogenic substrate.
    Hayashi S; Yamada K
    Thromb Res; 1981 Jun 1-25; 22(5-6):573-8. PubMed ID: 6171046
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of alpha 2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration, and an evaluation of the optimal urokinase dosage.
    Hayashi S; Yamada K
    Thromb Res; 1979; 16(3-4):393-400. PubMed ID: 92817
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
    Thorsen S; Müllertz S; Suenson E; Kok P
    Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor.
    Korninger C; Collen D
    Thromb Haemost; 1981 Oct; 46(3):662-5. PubMed ID: 6171907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.
    Collen D
    Eur J Biochem; 1976 Oct; 69(1):209-16. PubMed ID: 136345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibition of high and low molecular weight urokinase in plasma.
    Murano G; Aronson D; Williams L; Brown L
    Blood; 1980 Mar; 55(3):430-6. PubMed ID: 6444529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the complex between human alpha 2-macroglobulin and Crotalus adamanteus proteinase II. Release of active proteinase from the complex.
    Kress LF; Kurecki T
    Biochim Biophys Acta; 1980 Jun; 613(2):469-75. PubMed ID: 6160877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.